WASHINGTON, Nov. 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that NASDAQ halted trading of Vanda common stock this morning.
The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review Vanda's New Drug Application (NDA) for tasimelteon, proposed trade name HETLIOZ™, for the treatment of Non-24-Hour Disorder in the totally blind. The Advisory Committee meeting is scheduled for 8:00 am ET.
Vanda's HETLIOZ™ NDA is currently under Priority Review by the FDA with an action target date under the Prescription Drug User Fee Act (PDUFA-V) of January 31, 2014.
Investor Contact: Chad Rubin Vice President The Trout Group (646) 378-2947 email@example.com
Media Contact: Laney Landsman Assistant Vice President Makovsky (212) 508-9643 firstname.lastname@example.org
SOURCE Vanda Pharmaceuticals Inc.